Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.

Hill JA, Krantz EM, Hay KA, Dasgupta S, Stevens-Ayers T, Bender Ignacio RA, Bar M, Maalouf J, Cherian S, Chen X, Pepper G, Riddell SR, Maloney DG, Boeckh MJ, Turtle CJ.

Blood Adv. 2019 Nov 26;3(22):3590-3601. doi: 10.1182/bloodadvances.2019000717.

PMID:
31743392
2.

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, Hirayama AV, Sorror ML, Cherian S, Chen X, Cassaday RD, Till BG, Gopal AK, Sandmaier BM, Maloney DG, Turtle CJ.

Blood Adv. 2019 Oct 22;3(20):3062-3069. doi: 10.1182/bloodadvances.2019000593.

3.

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.

Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Aug 15;134(7):636-640. doi: 10.1182/blood.2019000905.

PMID:
31648294
4.

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.

Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra ED, Wu V, Voutsinas J, Shaw BE, Flynn KE, Lee SJ, Turtle CJ, Maloney DG, Fann JR, Bar M.

Biol Blood Marrow Transplant. 2019 Oct 9. pii: S1083-8791(19)30657-3. doi: 10.1016/j.bbmt.2019.09.037. [Epub ahead of print]

PMID:
31605820
5.

Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy.

Chou CK, Turtle CJ.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):780-784. doi: 10.1038/s41409-019-0602-5. Review.

PMID:
31431714
6.

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.

Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M.

Biol Blood Marrow Transplant. 2019 Aug 13. pii: S1083-8791(19)30517-8. doi: 10.1016/j.bbmt.2019.08.003. [Epub ahead of print]

PMID:
31419568
7.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC.

Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21. No abstract available.

PMID:
31056762
8.

Reply.

Lee DW, Mead E, Santomasso BD, Turtle CJ, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e211-e212. doi: 10.1016/j.bbmt.2019.03.019. Epub 2019 Mar 23. No abstract available.

PMID:
30910604
9.

Toxicities of CD19 CAR-T cell immunotherapy.

Hirayama AV, Turtle CJ.

Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. Review.

PMID:
30784102
10.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19.

PMID:
30782611
11.

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.

Tuazon SA, Li A, Gooley T, Eunson TW, Maloney DG, Turtle CJ, Linenberger ML, Connelly-Smith LS.

Transfusion. 2019 May;59(5):1773-1780. doi: 10.1111/trf.15178. Epub 2019 Feb 6.

PMID:
30729531
12.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ.

Blood. 2019 Apr 11;133(15):1652-1663. doi: 10.1182/blood-2018-11-883710. Epub 2019 Feb 6.

PMID:
30728140
13.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

14.

Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity.

Lindau P, Mukherjee R, Gutschow MV, Vignali M, Warren EH, Riddell SR, Makar KW, Turtle CJ, Robins HS.

J Immunol. 2019 Jan 15;202(2):476-483. doi: 10.4049/jimmunol.1800217. Epub 2018 Dec 12.

15.

Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.

Gust J, Taraseviciute A, Turtle CJ.

CNS Drugs. 2018 Dec;32(12):1091-1101. doi: 10.1007/s40263-018-0582-9. Review.

PMID:
30387077
16.

Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy.

Chung SH, Hughes G, Koffman B, Turtle CJ, Maloney DG, Acharya UH.

Bone Marrow Transplant. 2019 Apr;54(4):632-634. doi: 10.1038/s41409-018-0357-4. Epub 2018 Oct 5. No abstract available.

PMID:
30291306
17.

Driving CARs Across New Borders.

Turtle CJ, Adair JE.

Hum Gene Ther. 2018 May;29(5):529. doi: 10.1089/hum.2018.29065.cjt. No abstract available.

PMID:
29715075
18.

Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.

Gauthier J, Turtle CJ.

Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3. Review.

19.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

20.

CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era.

Hay KA, Turtle CJ.

Immunotherapy. 2018 Feb 1;10(4):251-254. doi: 10.2217/imt-2017-0162. No abstract available.

PMID:
29421980

Supplemental Content

Loading ...
Support Center